ID | 40503 |
JaLCDOI | |
フルテキストURL | |
著者 |
Nishimori, Hisakazu
Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Takahashi, Shunji
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Kiura, Katsuyuki
Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Ennishi, Daisuke
Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Kobayashi, Takayuki
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Sano, Koji
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Shinozaki, Eiji
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Yokoyama, Masahiro
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Mishima, Yuko
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Terui, Yasuhito
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Chin, Keisho
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Mizunuma, Nobuyuki
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Ito, Yoshinori
Division of Medical Oncology and Hematology, Cancer Institute Hospital
Nishimura, Seiichiro
Division of Breast Surgery, Cancer Institute Hospital
Takeuchi, Kengo
Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research
Ishikawa, Yuichi
Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research
Oguchi, Masahiko
Division of Radiology, Cancer Institute Hospital
Tanimoto, Mitsune
Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Hatake, Kiyohiko
Division of Medical Oncology and Hematology, Cancer Institute Hospital
|
抄録 | We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
|
キーワード | cancer of unknown primary site (CUP)
cisplatin
docetaxel
prognosis
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2010-10
|
巻 | 64巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 285
|
終了ページ | 291
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2010 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |